InspireMD Announces CFO Departure, Appoints Interim CFO & New Directors
Ticker: NSPR · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1433607
| Field | Detail |
|---|---|
| Company | Inspiremd, INC. (NSPR) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, board-change, personnel
TL;DR
CFO OUT, interim CFO IN, two new board members for InspireMD.
AI Summary
InspireMD, Inc. announced on December 10, 2024, the departure of its Chief Financial Officer, Robert L. Buono, effective immediately. The company has appointed Dr. Zvi Zilberman as interim CFO. Additionally, the company elected two new directors, Dr. Shimon Y. Ekstein and Mr. David M. J. M. Van den Broek, to its Board of Directors.
Why It Matters
The sudden departure of a CFO and the appointment of an interim successor can signal financial instability or strategic shifts, while new board members may bring fresh perspectives or influence future company direction.
Risk Assessment
Risk Level: medium — Changes in key executive positions and board composition can indicate underlying issues or strategic realignments that may impact the company's future performance.
Key Players & Entities
- InspireMD, Inc. (company) — Registrant
- Robert L. Buono (person) — Departing Chief Financial Officer
- Dr. Zvi Zilberman (person) — Interim Chief Financial Officer
- Dr. Shimon Y. Ekstein (person) — Newly Elected Director
- Mr. David M. J. M. Van den Broek (person) — Newly Elected Director
- December 10, 2024 (date) — Effective date of CFO departure and board changes
FAQ
Why did Robert L. Buono depart as CFO?
The filing states Robert L. Buono's departure was effective immediately, but does not provide a specific reason for his departure.
Who has been appointed as the interim CFO?
Dr. Zvi Zilberman has been appointed as the interim Chief Financial Officer.
When were the new directors elected?
The filing reports the election of two new directors, Dr. Shimon Y. Ekstein and Mr. David M. J. M. Van den Broek, as of December 10, 2024.
What is InspireMD, Inc.'s primary business?
InspireMD, Inc. is in the business of Surgical & Medical Instruments & Apparatus, as indicated by its Standard Industrial Classification code 3841.
What other items were filed along with this 8-K?
This 8-K filing includes information on the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
Filing Stats: 1,182 words · 5 min read · ~4 pages · Grade level 11.9 · Accepted 2024-12-12 07:22:24
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share NSPR The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex10-1.htm (EX-10.1) — 18KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-049727.txt ( ) — 273KB
- nspr-20241210.xsd (EX-101.SCH) — 3KB
- nspr-20241210_lab.xml (EX-101.LAB) — 33KB
- nspr-20241210_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INSPIREMD, INC. Date: December 12, 2024 By: /s/ Marvin Slosman Name: Marvin Slosman Title: Chief Executive Officer